- Home
- JELD vs FATE Comparison
JELD vs FATE Comparison
Compare JELD & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JELD | FATE |
|---|---|---|
| Founded | 1960 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 125.6M |
| IPO Year | 2016 | 2013 |
Fundamental Metrics
Financial Performance| Metric | JELD | FATE |
|---|---|---|
| Price | $1.89 | $2.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $3.43 | ★ $4.10 |
| AVG Volume (30 Days) | 1.4M | ★ 2.2M |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,211,181,000.00 | $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.93 | $0.93 |
| 52 Week High | $6.98 | $3.23 |
Technical Indicators
Market Signals| Indicator | JELD | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 74.17 | 55.49 |
| Support Level | $1.64 | $1.01 |
| Resistance Level | $2.06 | $2.88 |
| Average True Range (ATR) | 0.13 | 0.18 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 100.00 | 76.19 |
Price Performance
Historical ComparisonAbout JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.